We are live on ! Find out more
AVBP icon

ArriVent BioPharma
AVBP

99 hedge funds and large institutions have $732M invested in ArriVent BioPharma in 2025 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 25 increasing their positions, 30 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

189% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 9

36% more capital invested

Capital invested by funds: $539M → $732M (+$193M)

20% more funds holding in top 10

Funds holding in top 10: 5 → 6 (+1)

19% more funds holding

Funds holding: 83 → 99 (+16)

12.82% more ownership

Funds ownership: 85.46% → 98.29% (+13%)

17% less repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 30

Holders
99
Holders Change
+16
Holders Change %
+19.28%
% of All Funds
1.3%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.08%
New
26
Increased
25
Reduced
30
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IAM
Infinitum Asset Management
Florida
+$28.1M
2
SCM
Suvretta Capital Management
New York
+$22.3M
3
SL
Siren LLC
Connecticut
+$14.5M
4
F1I
Fund 1 Investments
Puerto Rico
+$11M
5
CLG
Cooperman Leon G
+$8.75M

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$6.26M
2
UBS Group
UBS Group
Switzerland
-$2.4M
3
OCA
Octagon Capital Advisors
New York
-$2.35M
4
Two Sigma Investments
Two Sigma Investments
New York
-$765K
5
Marshall Wace
Marshall Wace
United Kingdom
-$663K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$2.21M -$427K -20,584 -17%
UBS Group
27
UBS Group
Switzerland
$1.89M -$2.4M -115,597 -57%
MAP
28
Moody Aldrich Partners
Massachusetts
$1.56M +$1.49M +71,575 New
Wellington Management Group
29
Wellington Management Group
Massachusetts
$1.44M +$103K +4,981 +8%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$1.28M -$196K -9,447 -14%
Verition Fund Management
31
Verition Fund Management
Connecticut
$1.23M +$1.17M +56,502 New
WAM
32
Weiss Asset Management
Massachusetts
$1.17M +$1.12M +53,786 New
N
33
Nuveen
North Carolina
$1.04M +$70.2K +3,381 +8%
ECM
34
ExodusPoint Capital Management
New York
$1.04M +$526K +25,317 +114%
SAM
35
Sectoral Asset Management
Quebec, Canada
$775K +$529K +25,490 +253%
RhumbLine Advisers
36
RhumbLine Advisers
Massachusetts
$739K -$66.2K -3,189 -9%
Citadel Advisors
37
Citadel Advisors
Florida
$733K +$699K +33,655 New
Two Sigma Advisers
38
Two Sigma Advisers
New York
$725K +$318K +15,300 +85%
Bank of America
39
Bank of America
North Carolina
$669K +$30.4K +1,462 +5%
Susquehanna International Group
40
Susquehanna International Group
Pennsylvania
$645K -$149K -7,180 -20%
UBS AM
41
UBS AM
Illinois
$643K +$614K +29,555 New
AllianceBernstein
42
AllianceBernstein
Tennessee
$614K – – –
SG Americas Securities
43
SG Americas Securities
New York
$598K +$99.5K +4,793 +21%
Swiss National Bank
44
Swiss National Bank
Switzerland
$575K – – –
HF
45
HRT Financial
New York
$551K +$526K +25,346 New
Citigroup
46
Citigroup
New York
$470K -$262K -12,602 -37%
SPS
47
Susquehanna Portfolio Strategies
Pennsylvania
$437K +$416K +20,056 New
Deutsche Bank
48
Deutsche Bank
Germany
$383K -$116K -5,603 -24%
MIM
49
MetLife Investment Management
New Jersey
$372K – – –
Rafferty Asset Management
50
Rafferty Asset Management
New York
$343K -$34.5K -1,660 -10%
1
2
3 4 5

AVBP Hedge Fund Activity: Q2 2025 in Review

99 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in ArriVent BioPharma (AVBP) for Q2 2025, worth a combined $732M — up 36% from $539M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new AVBP positions and 9 closed out — a net gain of 17 holders — while 25 added to existing stakes and 30 trimmed.

The largest buyer was Infinitum Asset Management, adding an estimated $28.1M. The largest seller was BlackRock, cutting an estimated $6.26M.

  • 99 institutional investors held ArriVent BioPharma (AVBP) as of Q2 2025, up from 83 in Q1 2025.
  • Funds reported $732M of ArriVent BioPharma stock for Q2 2025, up 36% quarter-over-quarter.
  • 26 funds opened new ArriVent BioPharma positions in Q2 2025 and 9 closed out, a net change of +17 holders.
  • The largest ArriVent BioPharma buyer in Q2 2025 was Infinitum Asset Management, an estimated $28.1M added.
  • The largest ArriVent BioPharma seller in Q2 2025 was BlackRock, an estimated $6.26M sold.

Based on aggregated 13F filings for Q2 2025.